Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US drugmaker agreed to buy Metsera for...
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
Pfizer is closing in on a potential $7.3 billion takeover of weight-loss drug developer Metsera, the Financial Times reported on Sunday, citing unidentified sources. The U.S. pharma firm will acquire New York City-based...
Roche to acquire liver drug developer 89bio for up to $3.5 billion
Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight-loss drugs. The deal would help Roche...
Novo Holdings in talks to buy into Surya Hospitals
Novo Holdings, a 142 billion euro investment firm that controls drug maker Novo Nordisk, has entered into exclusive talks to acquire a 49% stake in Mumbai-based Surya Hospitals, said people familiar with the matter. A...
GTCR to Acquire Zentiva in $4.8 Billion Deal
Private equity firm GTCR has agreed to acquire Czech generic drugmaker Zentiva from Advent International in a transaction valued at €4.1 billion ($4.8 billion), according to reports in the Financial Times. The deal...
Dr Reddy’s inks pact with Johnson & Johnson to acquire vertigo treatment brand
Dr Reddy’s Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire the Stugeron brand across the EMEA regions, with India and Vietnam as key markets...
Private equity firm Advent to sell generic drugmaker Zentiva to GTCR
Czech generic drugmaker Zentiva said on Thursday that private equity group Advent International had agreed to sell the company to rival GTCR for an undisclosed value. The deal values the Prague-based company at slightly...
Private equity GTCR strikes $4.8 billion deal to buy Zentiva, FT reports
Private equity firm GTCR has struck a 4.1 billion euro ($4.8 billion) deal to buy Czech generic drugmaker Zentiva from Advent International, the Financial Times reported on Wednesday, citing unidentified sources...
Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on...
Singapore-based firm proposes to acquire 25% in Welcure Drugs & Pharma
Welcure Drugs & Pharmaceuticals Ltd on Wednesday said that Singapore-based Telexcell Trade has offered to acquire up to 25 per cent equity stake in the company at an indicative price of Rs 20 per share. This...
Aurobindo Pharma closing in on $5.5b Zentiva buyout
Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5-5.5 billion (Rs 43,500-47,900 crore) from Advent International, said several people aware of the matter...
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million
Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release. UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in...
